AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04887363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise
Description: Participants will receive 12-week, 60 minutes, 36-session Tai Chi exercise training class. Participants need complete baseline assessments of muscle performance, and balance ability measures 1 week prior and 1 week and 12 weeks following the intervention. All subjects will receive two post-exercise measurements at 13th week and 25th week.
Study NCT01099644 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 131 I-8H9
Description: Patients will be administered therapeutic dose of IP 131I-8H9 per the dose escalation regimen. 131I-8H9 pharmacokinetics will be studied by serial blood draws from indwelling venous lines. 131I-8H9 biodistribution will be studied by a single gamma camera scan about 5 days after IP injection where feasible.
Study NCT04578366 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy
Description: ESWT along with conventional therapy ESWT + hot pack(10min), ultrasound (5min), mobilizations, stretching, pendulum exercises, isometrics of shoulder
Study NCT04578366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: hot pack(10min), ultrasound (5min), mobilizations, stretching, pendulum exercises, isometrics of shoulder
Study NCT03740464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: long-acting granulocyte colony stimulating factor
Description: A 6 mg of polyethylene glycol granulocyte colony stimulating factor will be given to patients of study group
Study NCT03740464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Short-term granulocyte colony stimulating factor
Description: Short-term granulocyte colony stimulating factor will be given to all patients according to the severity of myelosuppression
Study NCT03740464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short-term granulocyte colony stimulating factor
Description: Short-term granulocyte colony stimulating factor will be given to all patients according to the severity of myelosuppression
Study NCT04306523 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: 4 months: observation of infant feeding behavior, behavior/temperament; bio-specimen collection; body composition, sucking intensity/frequency, activity intensity/frequency; maternal reports of feeding and behavior/temperament; maternal biospecimen. 6 month: behavior/temperament assessment, physical activity, and body composition. 12 month: Feeding behavior, behavior/temperament assessment, physical activity, and body composition. 24 month: maternal reports of children's eating behavior, behavior/temperament.
Study NCT03821961 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metabolic Surgery
Description: Roux-en-Y gastric bypass, Sleeve gastrectomy
Study NCT02254746 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Study NCT01469871 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dressing of wound
Description: The wound will be dressed using the Hypafix Transparent dressing after hip surgery.
Study NCT01469871 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dressing of wound
Description: The wound will be dressed using the Mepore Pro dressing after hip surgery.
Study NCT01469871 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dressing of wound
Description: The wound will be dressed using the Mepilex Border dressing after hip surgery.
Study NCT02144909 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partners in Care with Semi-Structured Support Group
Study NCT00744939 — intervention group
Intervention type: DRUG
Intervention: Gadopentetate dimeglumine (Magnevist, BAY86-4882)
Description: Patients will be followed for 2 years after the administration of Magnevist at the approved dose to see if symptoms consistent with NSF develop
Study NCT02744716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: low dose of Aspirin after operation
Study NCT02744716 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intrauterine balloon
Description: insert intrauterine balloon after operation
Study NCT04820907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1904-1
Description: Take it once daily for 8 weeks orally.
Study NCT04820907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RLD2001-1
Description: Take it once daily for 8 weeks orally.
Study NCT01739335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone Oral Tablet [Korlym]
Description: 2 Mifepristone 300 MG Oral Tablets once daily (600mg total) for 7 days
Study NCT01739335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 2 Placebo Oral Tablets once daily for 7 days
Study NCT02613130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stannous fluoride toothpaste
Study NCT02613130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium nitrate toothpaste
Study NCT01130844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMX Mesalamine
Description: 30 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
Study NCT01130844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMX Mesalamine
Description: 60 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
Study NCT01130844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMX Mesalamine
Description: 100 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
Study NCT02704754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suvorexant
Description: First in class orexin antagonist recently approved by the FDA for the treatment of insomnia
Study NCT02704754 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pill with inactive ingredients
Study NCT01386762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: 6 months of intense multi-modal exercise consisting of vibration exercise, gait training, electrical stimulation, etc.
Study NCT02002663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.2%
Description: PCA morphine 0.5 mg/ml bolus 1 mg LO 5 min max 20 mg in 4 hs
Study NCT04171323 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Participants will be completing a total of 40 computerized sessions.
Study NCT02002663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 1mg/kg
Study NCT02002663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline 0.9%
Study NCT04168242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scalp cooling Paxman Orbis II system
Description: The experimental arm will have scalp cooling that starts 30 minutes before the chemotherapy, continues throughout the infusion of the chemotherapy, and lasts for 20-90 minutes more depending on the type of regimen.
Study NCT04168242 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard treatment
Description: The control arm will not have scalp cooling before, during and after chemotherapy.
Study NCT01316614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FNA with and without a stylet
Description: If the patient agrees to enrollment in the study, the initial stage of the EUS exam will be performed in the usual manner. If a solid lesion that requires FNA is identified, an envelope will be opened which contains a computer generated randomization sequence for all passes. These sequences will be generated by a web-based program at http://www.randomizer.org/form.htm. Passes will be made based on the randomization, either with or without a stylet. Six passes (three with a stylet and three without a stylet) will be performed on solid lesions and four passes (two with and two without a stylet) will be performed on lymph nodes. Additional passes will be made at the discretion of the endosonographer as clinically indicated but will not be included in the data.
Study NCT03105011 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EpxDiabetes software
Description: Subjects will interact daily with a commercially available telemedicine product, Epharmix Diabetes (EpxDiabetes). They will each undergo a baseline blood draw to establish the control HgbA1C associated with standard of care. Three months later they will undergo an experimental blood draw to establish the HgbA1C associated with the use of EpxDiabetes. Between those procedures, the patient will interact with the intervention daily.
Study NCT00076570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Study NCT00076570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Study NCT04539275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: Convalescent plasma from persons recovered from SARS-CoV-2 is being used to treat hospitalized individuals with complicated COVID-19 infection.
Study NCT04539275 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Masked Saline Placebo
Description: 0.9% saline solution will be used as the Masked Saline Placebo
Study NCT02957552 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Description: Donor-specific, bone marrow derived mesenchymal stem (stromal) cells
Study NCT02669849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-210
Study NCT02669849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01687439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: 7.5mg/m2, D1-14
Study NCT01687439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: 25-30mg/m2, D1,8
Study NCT01687439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m2, D1-3
Study NCT04171323 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Cognitive Stimulation
Description: Participants will be completing a total of 40 computerized cognitive stimulation sessions.
Study NCT02535429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage
Study NCT00875498 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: active iTBS
Description: Intermittent Theta Burst Stimulation (iTBS) over Left dorsolateral prefrontal cortex.~80% MT, 20 sessions of 6 minutes, 2 per day
Study NCT00875498 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sham iTBS
Description: iTBS placebo (placebo coil)
Study NCT02187159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5565
Description: DS-5565 15 mg tablet for oral administration
Study NCT02187159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin 150 mg capsule for oral administration
Study NCT02187159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet
Description: Placebo tablet (matching DS5565) for oral administration
Study NCT02187159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet (matching DS5565) for oral administration
Study NCT02187159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet (matching DS5565) for oral administration
Study NCT02187159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Placebo capsule (matching pregabalin) for oral administration
Study NCT02187159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo capsule (matching pregabalin) for oral administration
Study NCT00899782 — intervention group
Intervention type: OTHER
Intervention: cytology specimen collection procedure
Description: correlative studies
Study NCT02662452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2222 single dose
Description: single ascending doses, oral suspension
Study NCT02662452 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo single dose
Description: single doses, oral suspension, matching placebo
Study NCT02662452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2222 multiple doses
Description: multiple ascending doses, daily for 14 days, oral suspension
Study NCT02662452 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo multiple doses
Description: multiple doses, daily for 14 days, oral suspension, matching placebo
Study NCT02601118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Micro Expression Training Tool
Description: The Micro Expression Training Tool (METT) and the Subtle Expression Training Tool (SETT) to help improve the non-verbal communication skills
Study NCT04285203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Video Intervention
Description: Educational videos
Study NCT03711344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The intervention will be administered by therapists working at community agencies who are experienced at providing Cognitive Behavioral Therapy.
Study NCT03711344 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: The intervention will be administered by therapists working at community agencies who are experienced at providing Cognitive Behavioral Therapy.
Study NCT02699723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: Given PO
Study NCT02699723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Given PO
Study NCT02699723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02423278 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Gastrectomy Plus D2 Lymphadenectomy
Description: This surgical procedure is performed by the same high-experienced surgical team as the control arm.~All lymph nodes around stomach (station 1\&2 LNs) must be removed to achieve a radical lymphadenectomy. Para-aortic lymph nodes should not be dissected even if a suspected lymph node metastasis is diagnosed from radiographic exams.
Study NCT02423278 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Gastrectomy Plus D4 Lymphadenectomy
Description: This surgical procedure is also performed by the same high-experienced surgical team as the control arm.~Lymph nodes around stomach (station 1\&2 LNs) and para-aortic lymph nodes must be removed during the operation.
Study NCT02423278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1+Oxaliplatin
Description: A perioperative chemotherapy, known as SOX regimen, should be performed in each enrolled patient with three-cycle treatments followed after a pathological carcinoma diagnosis. After a radical operation (arm groups), additional five-cycle treatments of adjuvant chemotherapy (SOX regimen) would be performed, followed by follow-up program. The treatment bundles are listed as follows:~* S-1: 40\~60mg bid，po, Day1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid）~* Oxaliplatin: 130mg/m2，iv drip for 2h，Day1
Study NCT01514253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose 25%
Description: 1 ml glucose 25%, once
Study NCT01514253 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Materna RTF Stage 1
Description: 1ml Materna RTF Phase 1, 2-3 minutes prior red-reflex examination.
Study NCT01514253 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water for Injection
Description: 1 ml Water for Injection (WFI), 2-3 minutes prior red-reflex examination
Study NCT01831947 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Study NCT01687439 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study NCT04596319 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AP-PA02
Description: Bacteriophage administered via inhalation
Study NCT04596319 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive Placebo administered via inhalation
Study NCT01248416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase Inhibitor
Study NCT01248416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth Hormone
Study NCT01248416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase Inhibitor and Growth Hormone
Study NCT03183908 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FLUAD®
Description: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
Study NCT03183908 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone® High-Dose
Description: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
Study NCT01688713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: The patients will receive Icotinib in doses of 250mg thrice per day until disease progression or undue toxicity.
Study NCT03890575 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Airway stent implantation
Description: The airway stents modified with 3D printing were implanted to treat malignant stricture involving carina and bronchi distal to carina.
Study NCT01060462 — intervention group
Intervention type: DRUG
Intervention: Pts. w/ neutropenic fever associated w/ hematologic malignancy
Description: Itraconazole 200 mg twice daily for 2 days for a total of 4 doses, then 200 mg once daily for 12 days. After 14 days of IV administration, itraconazole oral solution 200 mg twice daily should be continued for a total of 14 days until clinically significant resolution of neutropenia resolves
Study NCT00861081 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Management
Description: Over a period of one year, subjects will participate in two regular stroke clinics, three group clinics, obtain self-management tools, and will receive a series of four scheduled telephone calls by nurse practitioners to review information delivered during the group clinics and help with care coordination. Usual care will also be available.
Study NCT00861081 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written Materials
Description: Educational materials about stroke that will be distributed during the group clinic session will be mailed to these subjects. These materials have been developed by the American Heart Association. Usual care will also be available.
Study NCT03799861 — intervention group
Intervention type: OTHER
Intervention: Epoch 2: HBB with NeoBeat
Description: At the beginning of Epoch 2, all birth attendants in each of the 3 maternity units will participate in a 2 day workshop in Kinshasa in French that will include instructions regarding use of NeoBeat and training in HBB 2.0. Participants will be introduced to NeoBeat, which will include practice with NeoBeat using the NeoNatalie newborn simulator. This training will be conducted in French using typical adapted training materials for this program that incorporate placement of NeoBeat at appropriate times in the algorithm, including a flipchart and NeoNatalie. Participants will complete the pre and post knowledge check questionnaire for the training as well as the Observed Standardized Clinical Exams (OSCEs) with the incorporation of use of NeoBeat into the OSCEs.
Study NCT03799861 — intervention group
Intervention type: OTHER
Intervention: Epoch 3: HR-guided HBB
Description: At the beginning of Epoch 3, all birth attendants in each of the 3 maternity units will participate in a 1 day workshop in Kinshasa in French that will instruct them in an adapted, HR-guided HBB algorithm. This training will include simulation with NeoNatalie and NeoBeat. Participants will complete a pre and post knowledge check questionnaire for the training as well as the Observed Standardized Clinical Exams (OSCEs).
Study NCT00794144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine Hydrochloride Nasal Spray 0.6%
Description: one spray in each nostril twice daily for 2 weeks
Study NCT02652793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boosted atazanavir
Description: Atanazir 300 mg once dailly boosted with 100 mg of ritonavir once dailly
Study NCT02652793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Lamivudine 300 mg once dailly
Study NCT04642989 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: All movements of facial effleurage except applying pressure
Study NCT04642989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial Effleurage
Description: Facial massage to remove any lymphatic blockages
Study NCT04642989 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facial Effleurage
Description: Facial massage to remove any lymphatic blockages
Study NCT04642989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: Appropriate standard-of-care antibiotics as determined by the physician.
Study NCT04642989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: Appropriate standard-of-care antibiotics as determined by the physician.
Study NCT04642989 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Antibiotics
Description: Appropriate standard-of-care antibiotics as determined by the physician.